Prospective Validation of a Noninvasive Index for Predicting Liver Fibrosis in Hepatitis C Virus-Infected Liver Transplant Recipients

被引:15
作者
Benlloch, Salvador [1 ,3 ]
Heredia, Laura [2 ]
Barquero, Claudia
Rayon, Jose-Miguel [2 ,3 ]
Pina, Ramon
Aguilera, Victoria [1 ,3 ]
Prieto, Martin [1 ,3 ]
Berenguer, Marina [1 ,3 ,4 ]
机构
[1] La Fe Univ Hosp, Dept Hepatogastroenterol, Liver Unit, Valencia 46009, Spain
[2] La Fe Univ Hosp, Dept Pathol, Liver Unit, Valencia 46009, Spain
[3] La Fe Univ Hosp, Dept Gastroenterol, Valencia 46009, Spain
[4] Network Ctr Biomed Res Hepat & Digest Dis, CIBEREHD, Valencia, Spain
关键词
ANTIVIRAL THERAPY; SERUM MARKERS; BIOPSY; PANEL;
D O I
10.1002/lt.21919
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We previously developed a mathematical model, the Hospital Universitario La Fe (HULF) index, as an alternative to protocol liver biopsy (PLB) to estimate significant fibrosis (SF) in patients who underwent liver transplantation (LT) for liver damage caused by chronic HCV infection. In the present study, we sought to validate this noninvasive index. The commonly derived clinical and laboratory data for calculating the HULF index were prospectively collected over 2.7 years from patients undergoing LT and PLB. The sensitivity, specificity, positive and negative predictive values, and diagnostic capacity were evaluated with receiver operating characteristic curve analysis. Biopsy was performed 93 times in 86 LT patients. The prevalence of SF (F3-F4 on the Knodell scoring system) was 32%. The intraobserver and interobserver concordance was high (kappa = 0.94 and kappa = 0.75, respectively) in identifying SF in PLB. For low scores, the HULF index discarded an SF diagnosis with a sensitivity of 90% and a negative predictive value of 89%. The area under the receiver operating characteristic curve was 0.68. The precision of the HULF index did not improve with the incorporation of donor age and body mass index into the multivariate analysis. Applying the index would have prevented 24% of the biopsy procedures performed. In conclusion, the HULF index was prospectively validated with data commonly obtained in standard clinical practice. Because the index distinguishes a subgroup of HCV LT patients with a low probability of having SF, PLB would be avoided in those patients. Liver Transpl 15:1798-1807, 2009. (C) 2009 AASLD.
引用
收藏
页码:1798 / 1807
页数:10
相关论文
共 29 条
[1]   Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection [J].
Adams, LA ;
Bulsara, M ;
Rossi, E ;
Deboer, B ;
Speers, D ;
George, J ;
Kench, J ;
Farrell, G ;
McCaughan, GW ;
Jeffrey, GP .
CLINICAL CHEMISTRY, 2005, 51 (10) :1867-1873
[2]   Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? [J].
Afdhal, NH .
HEPATOLOGY, 2003, 37 (05) :972-974
[3]   Sampling variability of liver fibrosis in chronic hepatitis C [J].
Bedossa, P ;
Dargère, D ;
Paradis, V .
HEPATOLOGY, 2003, 38 (06) :1449-1457
[4]   Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index [J].
Benlloch, S ;
Berenguer, M ;
Prieto, M ;
Rayón, JM ;
Aguilera, V ;
Berenguer, J .
LIVER TRANSPLANTATION, 2005, 11 (04) :456-462
[5]   Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation [J].
Berenguer, M. ;
Palau, A. ;
Aguilera, V. ;
Rayon, J. -M. ;
Juan, F. S. ;
Prieto, M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (03) :679-687
[6]   Non-invasive biomarkers of liver fibrosis in liver transplant patients with hepatitis C: Can we avoid liver biopsies? [J].
Berenguer, M. .
DIGESTIVE AND LIVER DISEASE, 2009, 41 (03) :226-228
[7]  
Berenguer M, 2001, J HEPATOL, V35, P666, DOI 10.1016/S0168-8278(01)00179-9
[8]   Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients [J].
Berenguer, M ;
Prieto, M ;
San Juan, F ;
Rayón, JM ;
Martinez, F ;
Carrasco, D ;
Moya, A ;
Orbis, F ;
Mir, J ;
Berenguer, J .
HEPATOLOGY, 2002, 36 (01) :202-210
[9]   Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression [J].
Berenguer, M ;
Aguilera, V ;
Prieto, M ;
San Juan, F ;
Rayón, JM ;
Benlloch, S ;
Berenguer, J .
JOURNAL OF HEPATOLOGY, 2006, 44 (04) :717-722
[10]   Are posttransplantation protocol liver biopsies useful in the long term? [J].
Berenguer, M ;
Rayón, JM ;
Prieto, M ;
Aguilera, V ;
Nicolás, D ;
Ortiz, V ;
Carrasco, D ;
López-Andujar, R ;
Mir, J ;
Berenguer, J .
LIVER TRANSPLANTATION, 2001, 7 (09) :790-796